Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Suicide | 9 | 2023 | 145 | 3.160 |
Why?
|
| Antimanic Agents | 8 | 2022 | 31 | 2.340 |
Why?
|
| Bipolar Disorder | 9 | 2024 | 248 | 2.130 |
Why?
|
| Antipsychotic Agents | 10 | 2022 | 302 | 1.590 |
Why?
|
| Antidepressive Agents | 8 | 2017 | 228 | 1.490 |
Why?
|
| Valproic Acid | 4 | 2021 | 24 | 1.420 |
Why?
|
| Lithium | 5 | 2022 | 21 | 1.400 |
Why?
|
| Veterans | 12 | 2024 | 755 | 1.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 797 | 1.020 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2024 | 539 | 1.010 |
Why?
|
| Suicide, Attempted | 5 | 2022 | 111 | 0.960 |
Why?
|
| Lithium Compounds | 2 | 2015 | 9 | 0.920 |
Why?
|
| Schizophrenia | 4 | 2024 | 275 | 0.910 |
Why?
|
| Depressive Disorder | 5 | 2017 | 284 | 0.840 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 456 | 0.710 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 404 | 0.640 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2020 | 27 | 0.640 |
Why?
|
| Borderline Personality Disorder | 1 | 2018 | 14 | 0.580 |
Why?
|
| Suicidal Ideation | 3 | 2023 | 129 | 0.580 |
Why?
|
| Research Design | 3 | 2013 | 583 | 0.530 |
Why?
|
| Mental Disorders | 2 | 2015 | 811 | 0.520 |
Why?
|
| Parathyroid Diseases | 1 | 2015 | 3 | 0.480 |
Why?
|
| Hospitals, Veterans | 3 | 2016 | 159 | 0.470 |
Why?
|
| Humans | 38 | 2024 | 64729 | 0.470 |
Why?
|
| Thyroid Diseases | 1 | 2015 | 30 | 0.460 |
Why?
|
| Anticonvulsants | 2 | 2018 | 103 | 0.420 |
Why?
|
| Kidney Diseases | 1 | 2015 | 177 | 0.420 |
Why?
|
| Depression | 4 | 2013 | 889 | 0.410 |
Why?
|
| Memantine | 1 | 2013 | 22 | 0.400 |
Why?
|
| United States | 18 | 2024 | 8041 | 0.380 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 343 | 0.360 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 150 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2013 | 2086 | 0.320 |
Why?
|
| Death, Sudden | 1 | 2010 | 31 | 0.310 |
Why?
|
| Male | 21 | 2024 | 30790 | 0.310 |
Why?
|
| Patient Safety | 1 | 2012 | 247 | 0.300 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 66 | 0.300 |
Why?
|
| Lithium Carbonate | 1 | 2009 | 13 | 0.300 |
Why?
|
| Pharmacists | 2 | 2024 | 130 | 0.300 |
Why?
|
| Veterans Health | 3 | 2015 | 145 | 0.290 |
Why?
|
| Female | 21 | 2024 | 33739 | 0.290 |
Why?
|
| Propensity Score | 1 | 2009 | 188 | 0.290 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 461 | 0.280 |
Why?
|
| Quality of Health Care | 2 | 2024 | 524 | 0.280 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2016 | 382 | 0.280 |
Why?
|
| Employment | 1 | 2009 | 131 | 0.280 |
Why?
|
| Telemedicine | 2 | 2024 | 357 | 0.260 |
Why?
|
| Middle Aged | 16 | 2024 | 18106 | 0.260 |
Why?
|
| Clozapine | 2 | 2016 | 32 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 315 | 0.240 |
Why?
|
| Psychotropic Drugs | 1 | 2006 | 81 | 0.230 |
Why?
|
| Aged | 13 | 2024 | 14834 | 0.230 |
Why?
|
| Psychotherapy | 1 | 2006 | 101 | 0.230 |
Why?
|
| Medicaid | 1 | 2009 | 367 | 0.230 |
Why?
|
| Drug Synergism | 2 | 2017 | 143 | 0.230 |
Why?
|
| Videoconferencing | 1 | 2024 | 9 | 0.220 |
Why?
|
| Adult | 13 | 2024 | 17230 | 0.220 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 67 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2015 | 2603 | 0.200 |
Why?
|
| Mental Health Services | 2 | 2024 | 300 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2023 | 3299 | 0.180 |
Why?
|
| Patient Care Team | 1 | 2024 | 335 | 0.180 |
Why?
|
| International Classification of Diseases | 2 | 2013 | 136 | 0.180 |
Why?
|
| Psychometrics | 2 | 2016 | 392 | 0.170 |
Why?
|
| Self Report | 1 | 2023 | 390 | 0.170 |
Why?
|
| Restraint, Physical | 1 | 2021 | 49 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 706 | 0.160 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 20 | 0.160 |
Why?
|
| Social Isolation | 1 | 2020 | 38 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1135 | 0.160 |
Why?
|
| Adolescent | 6 | 2017 | 6291 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5758 | 0.150 |
Why?
|
| Inpatients | 1 | 2021 | 310 | 0.140 |
Why?
|
| Risk Factors | 4 | 2015 | 5393 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2017 | 6803 | 0.140 |
Why?
|
| Risk | 2 | 2016 | 376 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.130 |
Why?
|
| Off-Label Use | 1 | 2017 | 14 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 433 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 42 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 105 | 0.120 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 17 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 160 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 669 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 120 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 851 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2680 | 0.110 |
Why?
|
| Psychiatry | 1 | 2016 | 128 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 497 | 0.100 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 19 | 0.100 |
Why?
|
| Dementia | 1 | 2017 | 272 | 0.100 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 118 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2009 | 1274 | 0.100 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2013 | 13 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 90 | 0.100 |
Why?
|
| Interview, Psychological | 1 | 2013 | 79 | 0.100 |
Why?
|
| Prescription Drug Misuse | 1 | 2012 | 20 | 0.090 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 30 | 0.090 |
Why?
|
| Alcoholism | 2 | 2012 | 328 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2022 | 740 | 0.090 |
Why?
|
| Mental Health | 1 | 2015 | 360 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2013 | 202 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 250 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 258 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 219 | 0.090 |
Why?
|
| Young Adult | 4 | 2017 | 4771 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 665 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2013 | 316 | 0.080 |
Why?
|
| Child | 2 | 2010 | 4599 | 0.080 |
Why?
|
| Denmark | 1 | 2009 | 18 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2012 | 380 | 0.070 |
Why?
|
| Cause of Death | 1 | 2010 | 222 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 1115 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 142 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 5562 | 0.070 |
Why?
|
| Half-Life | 1 | 2008 | 81 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 90 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2009 | 179 | 0.070 |
Why?
|
| Placebos | 1 | 2006 | 73 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 2483 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 371 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 459 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1409 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 295 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2005 | 119 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 749 | 0.050 |
Why?
|
| Massachusetts | 1 | 2009 | 2137 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3745 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2024 | 489 | 0.050 |
Why?
|
| Morale | 1 | 2021 | 4 | 0.040 |
Why?
|
| Patient Isolation | 1 | 2021 | 7 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 40 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1689 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Medicare | 1 | 2021 | 615 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 151 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 308 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1555 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 246 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1159 | 0.020 |
Why?
|